Abbott Laboratories
I · Analyse IA
En bref
Abbott makes and sells healthcare products worldwide across four main areas: generic pharmaceuticals for chronic conditions, laboratory diagnostic systems and rapid tests, infant formula and nutritional products for children and adults, and medical devices including heart valves, glucose monitors, and pacemakers [Yahoo Finance]. The company serves hospitals, clinics, pharmacies, and consumers in both developed and emerging markets.
Abbott Laboratories is a diversified healthcare giant operating across four major segments: established pharmaceuticals, diagnostic products, nutritional products, and medical devices [Yahoo Finance]. The company generates $44.3B in annual revenue with strong margins and minimal debt, earning a perfect 10.0/10 financial health score [Yahoo Finance]. Recent strategic moves include a $21B acquisition of cancer diagnostics firm Exact Sciences and a pivot toward volume-driven nutrition sales, though the nutrition division contracted 6% in early 2026 [Yahoo Finance].
Abbott maintains exceptionally strong financial health with minimal debt, robust cash generation, and consistent profitability.
Score Sentinellis
10/10
Financially healthy
Capitalisation boursière
$154.7B
Chiffre d'affaires (12 mois)
$44.3B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
Yahoo Finance
- macro2026-05-18
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Yahoo Finance
- macro2026-05-19
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings
Yahoo Finance
- macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- macro2026-05-18
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
Yahoo Finance
- macro2026-05-18
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo
Yahoo Finance
Premium · gratuit avec tout compte
The nutrition division shrank 6% in early 2026 due to price increases that backfired by reducing customer purchases, loss of a major U.S. government contract for low-income family nutrition products, and persistently high raw material costs since the pandemic [Yahoo Finance]
Risques
4
Opportunités
6
Signaux d'alerte
2
Direction
10
21 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Abbott Laboratories
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 6 opportunités et 2 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?